



WEALTH WEEKLY

Weekly Alerts You Can Use!

Weekly View: Nifty, Bank Nifty:

Indices	CMP	Support	Resistance	50 DMA	200 DMA	Range	Preferred Trade
NIFTY	24271	23722	24551	23823	24869	23822-24522	Buy at CMP. Targets at 24551/24850. Aggressive targets at 25000-25200. Stop at 23722
BANK NIFTY	57939	56000	59000	55603	57218	56300-58899	Buy at CMP. Targets 58600/59000. Aggressive targets at 59700. Stop at 56000.

Medium Term Pick:

Stocks	CMP	Support	Resistance	50 DMA	200 DMA	Bias	Preferred Trade
LUPIN	2476	2239	2750	2311	2173	Positive	Lupin is no longer just a turnaround story—it is evolving into a high-quality global pharmaceutical company with multiple growth engines. Lupin has demonstrated strong operational turnaround and structural recovery over the last couple of fiscals, showcasing substantial growth in both top-line revenues and margin expansion. Its expanding US franchise, resilient India business, robust R&D pipeline, improving margins, and healthy balance sheet position it well for long-term compounding. Look to buy at CMP, and on dips between 2300-2350 zone, targeting 2553/2629, and then aggressive targets at psychological 2750 mark. Stop below 2239. Holding Period 9-12 Months.

Lupin Limited	BUY
CMP	2476
Target Price	2751
Stop	2239
52 Week H/L	2494/1837
P/E	19.6
EPS (TTM)	139.26
Promoter Holding/FIIs/DIIs/FIIs/Public	46.85%/21.70%/25.32%/6.13%
Book Value	491
Market Cap (INR)	113211

dominant market shares in Cardiovascular, Diabetology, Asthma/Respiratory, Pediatrics, Gastrointestinal, and Anti-Infectives. Historically, it was recognized as the world's largest manufacturer of anti-tuberculosis (TB) drugs.

Global Footprint: Reaches over 70 countries, operating world-class manufacturing units spread across India (such as Goa, Pune, Nagpur, Tarapur, and Pithampur) and advanced research setups globally, including Somerset, USA.

Leadership: Key operations are spearheaded by Vinita D. Gupta (CEO) and Nilesh Gupta (MD).

Fundamental Report (Financial Year 2025-26) : Lupin has demonstrated strong operational turnaround and structural recovery over the last couple of fiscals, showcasing substantial growth in both top-line revenues and margin expansion.

1. Key Stock & Valuation Financials : Current Market Price (CMP): ~₹2,476 (as of early July 2026) | Market Capitalization: ~₹1,13,207 Crore (Large Cap) | 52-Week High / Low: ₹2,494 / ₹1,837 | Price-to-Earnings (P/E) Ratio: ~21. | 1Price-to-Book (P/B) Ratio: ~4.052.

2) Core Income Statement Performance (Annualised Fy26) : The audited performance shows a distinct operational shift, driven by a reduction in raw material stress and strong performance in complex generics.

Metric	FY2025-26 (in ₹ Cr)	FY2024-25 (in ₹ Cr)	YoY Growth %
Total Revenue	₹27,958.00	₹22,707.90	↑ 23.1%
EBITDA	₹9,240.50	₹5,479.20	↑ 68.6%
EBITDA Margin	33.6%	24.7%	↑ 890 bps
Net Profit (PAT)	₹5,355.50	₹3,306.30	↑ 62.0%

3. Geographical Revenue Mix : Lupin relies on a diversified structural cushion, dividing its revenue evenly between export markets and reliable domestic sales:

North America (~36%): Concentrating aggressively on complex generics, inhalation products, and biosimilars. In fact, complex generics account for over half of its North American collections.

India Formulations (~34%): Driven primarily by the chronic therapeutic market (65% of domestic sales). Lupin ranks #2 in Respiratory and #3 in Diabetes Care across India.

Developed & Emerging Markets (~24%): Robust footprints in Europe, South Africa, Japan, and Australia.

API Sector (~5%): Pure backward-integrated bulk active pharmaceutical ingredients.

SWOT Analysis & Investment Outlook

Strengths & Catalysts

High-Margin Pipeline: Strong focus on complex generic launches (like respiratory inhalers and biosimilars) which shields it against standard pricing erosion in the US market.

Margin Expansion: Operating profit margins have leaped close to the mid-30s owing to cost optimization and favorable currency adjustments.

R&D spend of about 7.5% of sales | More than 430 ANDA filings | 344 USFDA approvals received | Strong pipeline in respiratory, injectables and complex generics

Compliance Clearance: It has successfully resolved historic USFDA regulatory regulatory hurdles, gaining Establishment Inspection Reports (EIR) for key factories like Somerset and Pithampur.

Risks to Keep in Mind

Regulatory Interventions: The generic pharmaceutical sector remains deeply sensitive to sudden pricing pressures and stringent USFDA audit compliances.

Elevated Valuation: Trading near its 52-week highs with a P/E expansion over 21x means near-term growth expectations are already factored in by the street.

Technically, Lupin is signaling a massive breakout on the upside with the sequence of higher high/low intact on all time frames. Momentum oscillator in bullish mode.

Look to buy at CMP, and on dips between 2300-2350 zone, targeting 2553/2629, and then aggressive targets at psychological 2750 mark. Stop below 2239. Holding Period 9-12 Months.

Lupin Limited: Technically Massive Breakout Play on Cards.

About Us: Overview of Lupin Limited

Lupin Limited is an Indian multinational pharmaceutical heavyweight based out of Mumbai. Founded in 1968 by Desh Bandhu Gupta (a former chemistry professor at BITS Pilani), the company started with a modest seed fund of ₹5,000. Today, it has scaled to become the 3rd largest pharmaceutical company in the U.S. by prescriptions, the 7th largest in India, and the 14th largest generic player globally.

Therapeutic Focus: Highly focused on chronic and complex therapies. It holds

Daily Chart of LUPIN :

